Nautilus Biotechnology (NASDAQ:NAUT) Stock Price Up 0.5% – Here’s What Happened

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) shares traded up 0.5% during trading on Tuesday . The company traded as high as $2.14 and last traded at $2.04. 258,565 shares were traded during trading, a decline of 25% from the average session volume of 346,353 shares. The stock had previously closed at $2.03.

Wall Street Analyst Weigh In

A number of analysts recently commented on NAUT shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nautilus Biotechnology in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Nautilus Biotechnology from a “sell” rating to a “hold” rating in a research note on Tuesday, November 18th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell” and an average price target of $2.50.

Nautilus Biotechnology Price Performance

The company has a 50-day moving average of $1.56 and a two-hundred day moving average of $1.03. The stock has a market capitalization of $257.67 million, a PE ratio of -4.08 and a beta of 1.48.

Nautilus Biotechnology (NASDAQ:NAUT) last posted its quarterly earnings results on Monday, October 27th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.04. On average, research analysts forecast that Nautilus Biotechnology, Inc. will post -0.57 EPS for the current fiscal year.

Hedge Funds Weigh In On Nautilus Biotechnology

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Corient Private Wealth LLC increased its stake in Nautilus Biotechnology by 860.0% during the second quarter. Corient Private Wealth LLC now owns 435,350 shares of the company’s stock worth $316,000 after acquiring an additional 390,000 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in shares of Nautilus Biotechnology in the 1st quarter valued at about $194,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of Nautilus Biotechnology during the 2nd quarter worth about $163,000. Jane Street Group LLC grew its holdings in shares of Nautilus Biotechnology by 304.1% during the 2nd quarter. Jane Street Group LLC now owns 290,369 shares of the company’s stock worth $210,000 after purchasing an additional 218,512 shares during the period. Finally, Clarius Group LLC increased its position in Nautilus Biotechnology by 22.4% during the 2nd quarter. Clarius Group LLC now owns 1,060,460 shares of the company’s stock worth $769,000 after purchasing an additional 193,874 shares in the last quarter. Institutional investors and hedge funds own 50.71% of the company’s stock.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.